The Week in Review: March 9 – March 16, 2018

Friday, March 16, 2018 News Recap: Canada: Treatment: Fantastic news from both BC and Quebec this last week:  All restrictions to treatment under the respective provincial PharmaCare plans have been removed!! See Chronic hepatitis C medication now available for all British Columbians, and Quebec Expands Patient Access to Chronic Hepatitis C Therapies. Grants Awarded to 13 Canadian Initiatives to Help Advance the Goal of Eliminating Chronic Hep...

Study shows shorter hepatitis C regimen effective in black patients

Boston, MA - A study by the Harvard Pilgrim Health Care Institute found that contrary to current hepatitis C treatment guidelines, an eight-week treatment regimen may be just as effective as 12 weeks in black patients. The new study of more than 2,600 patients in Kaiser Permanente's Northern California region also showed that more people overall could take advantage of the shorter treatment duration, which has important implications for access given the m

Shorter duration of glecaprevir-pibrentasvir effective against hepatitis C virus: The ENDURANCE trials

Treatment options for patients with chronic HCV continue to evolve, and effective agents with shorter treatment duration are needed to decrease morbidity. The coformulation of the nonstructural (NS) 3/4A protease inhibitor glecaprevir and NS5A inhibitor pibrentasvir was approved for the treatment of patients with HCV genotypes 1-6 without cirrhosis has demonstrated pangenotypic efficacy, a favorable safety profile, high barrier to resistance, and synergist

The Week in Review: April 21, 2017 – April 28, 2017

Friday, April 28, 2017 News Recap Canada New Canadian Testing Guidelines Released: On April 24, 2017, The Canadian Task Force on Preventative Health Care (CTFPHC) published its HCV Screening Guidelines in the CMAJ. The guidelines make the recommendation to continue screening those with known risk factors, but does not include a recommendation to screen the age cohort born between 1945-1975, which has been recommended by many of Canada’s top liver sp...

AbbVie takes aim at Gilead and BMS with 8-week hep C treatment

AbbVie is aiming to steal sales from hep C drugs from Gilead and BMS with a new combination offering a shorter, eight-week treatment for the most difficult-to-treat form of the disease. Results presented at the International Liver Congress (ILC) in Amsterdam showed 95% of genotype 3 patients on its pan-genotypic regimen of glecaprevir+pibrentasvir were free of disease, 12 weeks after completing an eight-week treatment course. The results were based on

The Week in Review: Jan 27, 2017 – Feb 3, 2017

Friday, February 3, 2017 News Recap Hepatitis C and Rheumatic, Kidney & Heart Disease As you may remember there have been quite a few news items over the past few months about the extrahepatic effects of hepatitis C, which is more and more coming to be recognized as a multi-organ disease.  Not only is the hepatitis C virus (HCV) the cause of liver diseases in up to 170 million people worldwide, it also has many extrahepatic disease manifestation...

Health Canada Grants Priority Review to AbbVie’s Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

If approved, G/P may provide a shorter, eight week, once-daily, ribavirin-free treatment option for the majority of HCV patients without cirrhosis AbbVie's New Drug Submission is supported by data from its global registrational clinical development program across all major HCV genotypes and in patients with specific treatment challenges MONTREAL, Feb. 1, 2017 /CNW/ - AbbVie, a global biopharmaceutical company, today announced it has sub...

Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection

Phase 2 Data Presentations at The Liver Meeting ® Detail SVR12 Rates from Two Studies as Well as SVR8 Rates in Patients for Whom Direct-Acting Antiviral Treatment Previously Failed KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three Phase 2 clinical trials evaluating MK-3682B (MK-3682/grazoprevir/ruzasvir1), the company’s investigational all-oral,

Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes of Chronic Hepatitis C

 97.5 percent of chronic HCV infected patients without cirrhosis and new to treatment across all major genotypes (GT1-6) achieved SVR12 with 8 weeks of G/P Across the 8-week arms of three registrational studies, no patients discontinued treatment due to adverse events G/P is an investigational, pan-genotypic, once-daily, ribavirin-free regimen for the treatment of chronic HCV NORTH CHICAGO, Ill., Nov. 11, 2016 /PRNewswire/ -- AbbVie (N...

Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV

- Ongoing Phase 2 development focusing on triple combination for treatment durations as short as six weeks for broad HCV population – PARIS, Sept. 23, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced that updated interim results were presented today in an ePoster describing a phase 2 study being conducted by Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies (Janssen) at the European Association for the Stu...